Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma

Allergy. 2021 Jul;76(7):2238-2241. doi: 10.1111/all.14737. Epub 2021 Jan 26.

Authors

Grainne d'Ancona¹, Joanne E Kavanagh^{1

2}, Jaideep Dhariwal^{1

2}, Andrew P Hearn^{1

2}, Cris Roxas¹, Mariana Fernandes¹, Linda Green¹, Louise Thomson¹, Alexandra M Nanzer^{1

2}, David J Jackson^{1

2}, Brian D Kent^{1

3

4}

Affiliations

¹ Guy's Severe Asthma Centre, Guy's and St Thomas' Hospitals, London, UK.
² Asthma UK Centre, King's College London, London, UK.
³ Department of Respiratory Medicine, St James' Hospital, Dublin, Ireland.
⁴ School of Medicine, Trinity College Dublin, Dublin, Ireland.

PMID: 33432682
DOI: 10.1111/all.14737

No abstract available

Publication types

Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Eosinophils
Humans
Pulmonary Eosinophilia* / drug therapy

Substances

Adrenal Cortex Hormones
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
benralizumab